Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03793400

Enrollment

Registered

2019-01-04

Start date

2018-03-13

Completion date

2018-12-28

Last updated

2019-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choroidal Neovascularization, Punctate Inner Choroidopathy

Keywords

punctate inner choroidopathy, multifocal choroidits, choroidal neovascularization, anti-VEGF, long-term outcome

Brief summary

To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.

Detailed description

To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment. The age, sex, best corrected visual acuity (BCVA) in Snellen chart, and refractive status for each patient were recorded. All patients had thorough clinical examinations, including slit lamp biomicroscopy, indirect ophthalmoloscopy, and spectral domain optical coherence tomography during each visit. Fundus photography, fluorescein angiography, and indocyanine angiography were performed on all patients. OCT angiography was performed.

Interventions

DRUGBevacizumab Injection

Anti-vascular endothelial growth factor (VEGF)

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Patients were punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization. 2. Follow up over 4 years.

Exclusion criteria

1. Patients were not punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization 2. Patients were punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization but loss follow over 1 year.

Design outcomes

Primary

Measure	Time frame	Description
Wilcoxon Signed-Rank test	Baseline,48 month.	A statistical comparison of average of two dependent samples

Secondary

Measure	Time frame	Description
visual acuity	Baseline,48 month.	visual acuity in logMAR

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026